Ferndale Laboratories competitors

Mr. Ward has been a member of our Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer. Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of Sightline Opportunity Management Fund II, LLC, and may provide limited advisory and consulting services to Sightline Partners in this capacity.

Tom co-founded Dermira in 2010 and is our Chief Executive Officer and Chairman of our board of directors. Tom brings over 25 years of experience in specialty pharma and 18 years of experience in dermatology. Prior to founding Dermira, Tom served as Chairman of the board of directors and Chief Executive Officer of Peplin, Inc. until Peplin’s acquisition by LEO Pharma A/S in 2009. Previously, Tom served as Chairman of the board of directors and Chief Executive Officer of Connetics Corporation until Connetics was acquired by Stiefel Laboratories, Inc. in 2006. Prior to Connetics, Tom served as President and Chief Operating Officer of CytoTherapeutics Inc., and in various management positions at Ares-Serono S.A., including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Tom began his career with Eli Lilly and Company. Tom has served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx Pharmaceuticals, Inc., until its acquisition by Amgen in 2013, Sangamo Biosciences, Inc., Lithera and Somaxon Pharmaceuticals, Inc. In addition, Tom is Chairman of the Biotechnology Institute, a non-profit educational organization, and is a member of the board of trustees of the University of Kansas Endowment Association. Tom holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.

John Fraher is a Chief Executive Officer at Aptalis Pharma Inc, Chief Executive Officer at Eurand NV, and Board Member at Ellodi Pharmaceuticals and is based in United States. He has worked as Pres:Aptalis Pharma Technologies at Aptalis Pharma Inc, Production Manager at Fort Dodge Animal Health, and President at Aptalis Pharma Inc. John works or has worked as President:America at Eurand Pharmaceuticals Hldg. He attended University College Dublin between 1984 and 1989.

Haruo Naito is a Board Member at Eisai. He has worked as Director at Eisai, President/CEO at Eisai, and Executive Vice President at Eisai. Haruo works or has worked as CHAIRMAN at The Naiito Foundation. He attended Keio University and Northwestern University.

Country Manager enabling teams to deliver the present and charter the future aspirations, setting vision, strategising to capitalise on emerging opportunities in India and South Asian regions. P&L leader with multiple TA domain expertise, and across geographies in leading MNC,Indian companies with cultural diversity. Expertise in healthcare Sales& Marketing, Strategy, Business operations, new business venture management, strategic planning, managing acquisition, strategic alliance management, and International Business ( Includes Indian subcontinent of Srilanka, Bangladesh, Pakistan, Maldives etc), and exposure across AP markets. Expertise in leading profitable growth at South west Asia cluster country level. specialty,chronic and mass base business units across leading MNC & Indian companies.Setting up of Key Account Management and international business.